Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis.

ABSTRACT:

Importance

Topical medication is the central treatment for patients with atopic dermatitis (AD), but the options are limited. Phosphodiesterase 4 (PDE4) inhibitors are a new candidate for AD therapy.

Objective

To evaluate the efficacy and safety of topical PDE4 inhibitors in mild to moderate AD.

Data sources

Clinical trials were identified from MEDLINE, Embase, Cochrane Controlled Register of Trials, Chinese medical databases (Wanfang, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature Database, and China Science and Technology Journal Database), ClinicalTrials.gov, and other trial registries from inception to August 15, 2018. No restrictions on languages were placed.

Study selection

Only double-blind randomized clinical trials with topica

SUBMITTER: Yang H 

PROVIDER: S-EPMC6507295 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature